louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00273143: A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
Official title: Kinetics of Cytomegalovirus (CMV) Replication and CMV-specific Immune Reconstitution After Hematopoietic Stem Cell Transplantation.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cytomegalovirus Infection
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2006-01-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: rticipants who will be undergoing blood marrow or stem cell transplant and donors that are 18 years of age or older, may be eligible to participate in this study.

Brief summary: This study is being done to determine how the body fights off a common virus known as Cytomegalovirus (CMV). CMV is a virus that commonly infects humans and causes disease in patients with compromised immune function such as those who receive organ and tissue transplant. By knowing how the human body responds to the infection, researchers will be able to develop better methods on how to prevent this infection.

Detailed description: This study is looking at the CMV virus in Hematopoietic stem cell donors and recipients. In the donor population, the study is looking at the participants blood to see if they contain cells that are active against the virus. Information about the donor will be obtained through an interview and through review of medical records. A blood sample will be drawn at the time of the donor's evaluation, which will take place in conjunction with the regular blood tests that are ordered. Participants of the study who are donors will only be involved in the study at the time of blood collection.

Participants who will be receiving hematopoietic stem cell transplantation will have data collected through an interview and review of medical records. Participants will have blood drawn prior to transplant, weekly for 12 weeks and then monthly for three months following transplant. In addition, if CMV disease develops during this period of time, blood will be drawn till the participant is cured for the disease. All blood draws for thes study will take place in conjunction with the regular routine blood work. Participants will be in the study for one year after transplant.

Eligibility criteria: Participants who will be undergoing blood marrow or stem cell transplant and donors that are 18 years of age or older, may be eligible to participate in this study.

Primary outcomes:
measure: To characterize the kinetics of CMV-specific immunity after HSCT.
measure: To characterize the kinetics of CMV replication after HSCT.
measure: To assess the degree of Epstein-Barr virus (EBV), human herpesvirus (HHV)-6 and HHV-7 replication after HSCT.
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Raymund R. Razonable, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02424643: Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study
Official title: Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2015-04-23
Enrollment: 1131
Sex: MALE
Minimum age (years): 18
Maximum age (years): 34
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to test the efficacy of alternative methods to improve survey completion.

Detailed description: Men who have sex with men (MSM) are the risk population most heavily impacted by HIV in the United States by any measure; in 2009, at least 61% of new HIV infections were estimated to have occurred in MSM. MSM are experiencing an increase in HIV transmission that has been occurring since at least 1990, and accelerated in multiple North American and European countries from 2000-2005. The expansion of the HIV epidemic has been proposed to be attributable, in part, to the extent to which the internet has facilitated sexual connectivity among MSM.

Researchers have attempted to reach MSM for HIV prevention research and intervention on the internet. In the past 10 years, there has been a proliferation of internet surveys and HIV research studies among men who have sex with men that utilize the internet for data collection and, in some cases, the delivery of HIV prevention content. The development of internet-based interventions has been recently identified as especially promising because of its potential for scalability. However, there are also important limitations to internet-based data collections and prevention studies. The most important of these relate to representativeness and opportunities to introduce bias to data collections and differences in access to and use of internet among different subgroups of MSM. Equally important, although less discussed, are the unique ethical and human research protections challenges posed by online sexual health prevention studies.

The investigators will conduct an experiment to improve knowledge of how to conduct internet-based HIV prevention research with MSM in ways that decrease biases in data collections. The design will consist of a randomized controlled trials of MSM recruited online. A total of 1000 MSM will be enrolled to determine how to best improve retention in online surveys.

Eligibility criteria: Inclusion Criteria:

* male
* aged 18 to 34 years
* have had sex with another man in the past 12 months

Exclusion Criteria:

* female or transgender
* younger than 18 years of age
* older than 34 years of age
* have not had sex with another man in the past 12 months.

Primary outcomes:
measure: Proportion of survey completed before dropping out.
timeFrame: At baseline survey
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Rollins School of Public Health, Emory University
state: Georgia
Study officials:
References:
Clinical trial NCT01353690: Autologous Cell Therapy for Ischemic Heart Failure
Official title: A Prospective, Multicenter, Feasibility Study of Autologous Muscle-derived Cell (AMDC) Transplantation for Treatment of Advanced Ischemic Heart Failure
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Ischemic Heart Disease
Keywords: Cell Therapy
Heart Failure
Heart Disease
Myocardial Infarction
Myocardial Ischemia
Autologous
Muscle-derived Cell
Lead sponsor: Cook MyoSite
Sponsor class: INDUSTRY
First posted: 2011-05-16
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle-derived Cells (AMDC; a preparation of a patient's own cells) as a treatment for patients with advanced heart failure caused by ischemia.


Eligibility criteria: Inclusion Criteria:

* Age greater than 18 but less than 80 years
* Prior myocardial infarction
* Depressed left ventricular ejection fraction (LVEF) ≤ 35%
* NYHA functional classification of II to IV

Exclusion Criteria:

* Not under stable optimal medical management
* Cardiac surgery or percutaneous coronary intervention within 3 months
* Occurrence of myocardial infarction (MI) within 6 months, in the case of first MI, or 3 months, in the case of any subsequent MI
* Prior cell, gene, or transmyocardial laser revascularization therapy
* Ventricular wall thickness in target region ≤ 5 mm
* Moderate to severe aortic valve stenosis or mechanical valve replacement
* Left ventricular aneurysm or thrombus
* Left ventricular dysfunction associated with a reversible cause
* Vascular disease preventing percutaneous vascular access
* History of myopathic disease
* History of neoplasia within 5 years, except for basal cell carcinoma
* Receiving or planning to receive anti-cancer medications
* Serum creatinine \> 3.0 mg/dl
* Pregnant, planning to become pregnant, or breastfeeding a child in the next 18 months
* Life expectancy of less than 1 year
* Morbid obesity (defined as BMI \> 35)
* History of bleeding diathesis or coagulopathy
* Positive for HIV, Hepatitis B, or Hepatitis C
* Known hypersensitivity or contraindication to study product or treatment procedure
* Enrolled in another research project at the time of enrollment
* Unable to provide informed consent
* Unable or unwilling to commit to the follow-up clinical procedures

Primary outcomes:
measure: Incidence of major adverse events associated with the use of AMDC
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta and Mazankowski Alberta Heart Institute
state: Alberta
city: Montreal
country: Canada
facility: Montreal Heart Institute
state: Quebec
Study officials:
affiliation: Montreal Heart Institute
name: Hung Q. Ly, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06336590: Student Exercise and Sleep Timing Study - Part 2
Official title: Student Exercise and Sleep Timing Study - Part 2
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sleep
Mood
Stress
Keywords: Exercise
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
First posted: 2024-03-29
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 23
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to examine the effects of a morning exercise intervention on sleep (quality and duration), mood (positive affect, anxiety, depression, anger), stress and productivity among undergraduate students (18-23 years) evening-exercisers with poor self-reported sleep quality.

Aim 1. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit improved sleep quality (increased efficiency, decreased fragmentation) and increased sleep duration.

Aim 2. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit improved mood (increased positive affect, decreased depression, anxiety and anger).

Aim 3. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit decreased stress and increased productivity.


Eligibility criteria: Inclusion Criteria:

* Healthy undergraduates (18-23 years)
* Frequent evening exercisers (6pm-11pm, 3+ times per week)
* Poor self-reported sleep quality
* Must be willing to wear wrist actigraph 24/7 except when showering/bathing

Exclusion Criteria:

* Sleep/circadian rhythm disorders
* Medications for sleep
* Inability to change schedule to exercise in AM
* Inability to maintain exercise frequency over next 4 weeks

Primary outcomes:
measure: Sleep Quality
timeFrame: 2 weeks
Secondary outcomes:
measure: Mood
timeFrame: 2 weeks
measure: Stress
timeFrame: 2 weeks
measure: Productivity
timeFrame: 2 weeks
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: College Avenue Gym
state: New Jersey
city: New Brunswick
country: United States
facility: Cook/Douglass Rec Center
state: New Jersey
city: New Brunswick
country: United States
facility: Rutgers Fitness Center
state: New Jersey
city: New Brunswick
country: United States
facility: Rutgers Sleep Lab
state: New Jersey
city: Piscataway
country: United States
facility: Livingston Rec Center
state: New Jersey
city: Piscataway
country: United States
facility: Werblin Rec Center
state: New Jersey
Study officials:
affiliation: Rutgers, The State University of New Jersey
name: Andrea Spaeth, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03939390: Follicular Phase Stimulation vs. Luteal Phase Stimulation in Patients Diagnosed With Suboptimal Response
Official title: Conventional Stimulation in Follicular Phase vs. Luteal Phase Stimulation in Patients With Suboptimal Response. Randomized Clinical Trial. SUBLUTEAL Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Improving Ovarian Stimulation; Suboptimal Responders
Lead sponsor: Instituto Bernabeu
Sponsor class: OTHER
First posted: 2019-05-06
Enrollment: 41
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 41
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the difference in the number of oocytes obtained by performing ovarian stimulation in follicular phase vs. luteal phase in a population of patients with previous suboptimal response.

This is a controlled randomized clinical study.

We aim to include 41 patients diagnosed with suboptimal response who will undergo an ovarian stimulation in order to vitrify and accumulate oocytes.

The main variable for evaluating the efficacy in this exploratory study will be the number of oocyte cumulus complexes obtained.


Eligibility criteria: Inclusion Criteria:

* Meets Bologna criteria to be diagnosed as poor responder
* Less than 10 oocytes obtained in a prior controlled protocol of conventional ovarian stimulation
* Age \< 41 years
* Body Mass Index (BMI) between 18 and 32 kg/m2
* Regular menstrual cycles between 21 and 35 days.
* Indication for in vitro fertilization
* Indication to start stimulation with 150mcg of corifollitropin alpha
* Presence of both ovaries
* Ability to participate and comply with study protocol
* Signing an informed consent form

Exclusion Criteria:

* Presence of follicles larger than 10 mm in the randomization visit
* Endometriosis stage III/IV
* Patients with less than 4 oocytes in previous ovarian stimulation and poor ovarian reserve parameters (as per Bologna criteria)
* Concurrent participation in another study

Primary outcomes:
measure: number of oocytes
timeFrame: at the end of stimulation
Secondary outcomes:
Other outcomes:
Locations:
city: Alicante
country: Spain
facility: Instituto Bernabeu
Study officials:
References:
Clinical trial NCT03553290: Therapeutic Evaluation of Lower-level Laser for Treating Dentinal Hypersensitivity
Official title: Lower-level Laser for Treating Dentinal Hypersensitivity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dentinal Hypersensitivity
Keywords: Dentistry
Dentinal Hypersensitivity
lower-level laser therapy
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2018-06-12
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Split-mouth design in the same individual
Primary purpose: TREATMENT

Brief summary: The aim of this study was to evaluate the efficacy of low energy laser for the treatment of dentinal hypersensitivity due to periodontal therapy.

Detailed description: We will recruit 80 adult patients with obvious symptom of hypersensitivity after periodontal therapy. They will receive low-energy laser treatment, and the area without the symptom of hypersensitivity will be served as control. Changes in pain status and clinical periodontal index within six months of treatment will be recorded.

Eligibility criteria: Inclusion criteria

1.20-80 year-old with their own will and oral cleaning ability 2.Patients who have been diagnosed with periodontitis and have completed periodontal treatment 3.Gingival recession in at least two regions showed sensitivity of teeth (VAS\> 5) 4.No systemic infection 5.No painkillers in the past two weeks 6.Not pregnant or lactating

Exclusion criteria

1.Smoking more than half a pack a day in the past month

Primary outcomes:
measure: Change in mental status
timeFrame: 6 months
Secondary outcomes:
measure: Change in probing depth
timeFrame: 6 months
measure: Change in clinical attachment level
timeFrame: 6 months
measure: Change in gingival recession
timeFrame: 6 months
measure: Change in masticatory mucosa
timeFrame: 6 months
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Po-Chun Chang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04614090: Fast Reversal of Warfarin and Early Surgery in Patients With Trochanteric Hip Fracture A Case-control Study
Official title: Is Fast Reversal and Early Surgery (Within 24 h) in Patients on Warfarin Medication With Trochanteric Hip Fractures Safe: A Case-control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Trochanteric Hip Fractures
Warfarin Medication
Early Surgery
Keywords: Hip fracture
Surgical treatment
Warfarin
Anticoagulation treatment
Intramedullary nailing
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: Stockholm South General Hospital
First posted: 2020-11-03
Enrollment: 198
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients on warfarin, with low-energi trauma, \>60years, mean 86 years Op at Stockholm South General Hospital (södersjukhuset) between (Jan 1,2011 - Dec 31,2014) Follow-up 1 year, all pat op within 24 hours from hospital arrival to the surgery. Operated with Intramedullary nail due to unstable intertrochanteric (OTA/AO 31A2, A3) or Subtrochanteric fracture (OTA/AO 32A,32B,32C).

Brief summary: A retrospective case-control study. To evaluate if early surgery within 24hours of troch or subtrochanteric hip fractures using intramedullary nailing is safe in patients on warfarin treatment after fast reversal of the warfarin effect


Eligibility criteria: Exclusion Criteria:

* Pathological fracture
* Late presentation to the hospital
* Other injuries

Primary outcomes:
measure: Transfusion rates
timeFrame: Pre-surgery
measure: Transfusion rates
timeFrame: Pre-surgery
measure: Transfusion rates
timeFrame: During the surgery
measure: Transfusion rates
timeFrame: During the surgery
measure: Transfusion rates
timeFrame: 2-4 days after the surgery
measure: Transfusion rates
timeFrame: 2-4 days after the surgery
measure: adverse events
timeFrame: Immediately after the surgery
measure: mortality
timeFrame: Immediately after the surgery
measure: mortality
timeFrame: 30-days after the surgery
measure: mortality
timeFrame: 1 year after the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Södersjukhuset
state: Sjukhusbacken 10
Study officials:
affiliation: Stockholm South General Hospital
name: Leif Mattisson
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mattisson L, Lapidus LJ, Enocson A. Is fast reversal and early surgery (within 24 h) in patients on warfarin medication with trochanteric hip fractures safe? A case-control study. BMC Musculoskelet Disord. 2018 Jun 26;19(1):203. doi: 10.1186/s12891-018-2126-3.
Clinical trial NCT06155890: Restoring Mobility: Roles of Percutaneous Consolidation for Pelvic Ring Bone Lesions
Official title: Restoring Mobility: Roles of Percutaneous Consolidation for Pelvic Ring Bone Lesions -a Multicenter Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pelvic Ring Tumor Lesions
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2023-12-05
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with cancer who underwent percutaneous screw fixation or cementoplasty either for prophylactic consolidation or treatment of pathologic fractures in pelvic ring tumors.

Brief summary: Evaluate early functional outcomes following percutaneous screw fixation or cementoplasty for pelvic ring tumor lesions.


Eligibility criteria: Inclusion :

- Individuals with cancer who underwent percutaneous screw fixation or cementoplasty either for prophylactic consolidation or treatment of pathologic fractures in pelvic ring tumors.

Exclusion criteria :

* minors
* incompetent adults
* refused to participate in the study
* pregnant women

Primary outcomes:
measure: postoperative weight-bearing ambulation
timeFrame: During hospitalization, mainly less than 3 days
Secondary outcomes:
measure: Adverse event
timeFrame: During hospitalization, and follow-up
measure: Duration of hospitalization
timeFrame: Mainly less than 3 days
measure: Long-term effectiveness in preventing pathological fractures of the pelvic ring
timeFrame: 3 months after the procedure, and during follow-up, up to 5 years
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU NICE
Study officials:
References: